What moved PRFN.SW stock today?

PRFN.SW stock dropped **8.12%** largely on volume heating to **2,937,350** shares. The move linked to heavy intraday selling placed price near the year low. Traders cite liquidity and lack of fresh catalysts.

What are the valuation metrics for PRFN.SW?

Key metrics show EPS **-0.001**, PE **-36.20**, enterprise value **CHF 305,000**, current ratio **1.27**, and negative book value per share. These reflect a development-stage balance sheet.

What targets does Meyka AI give for PRFN.SW stock?

Meyka AI's forecast model projects a base case **CHF 0.0500** (+38.12%), bullish **CHF 0.1000** (+176.24%), and downside **CHF 0.0200** (-44.75%). Forecasts are model projections and not guarantees.

Should traders buy PRFN.SW after the intraday drop?

This is speculative. Short-term traders may trade the volatility with tight stops. Long-term investors should wait for clinical or financing clarity given negative earnings and thin liquidity.

CH Stocks

PRFN.SW Kinarus Therapeutics (SIX) -8.12% to CHF0.0362 09 Jan 2026: heavy volume

ByDanny Kontos January 9, 2026

PRFN.SW stock fell 8.12% intraday to CHF 0.0362 on 09 Jan 2026, driven by a volume surge to 2,937,350 shares. The move places Kinarus Therapeutics Holding AG among the most active names on the SIX market today. Traders are watching the wide gap versus the 50-day average of CHF 0.07275 and the 200-day average of CHF 0.07420, as the small-cap clinical-stage group trades well below recent averages and year high.